ACADIA-JPM-20240109 .pdf

1、Steve Davis,CEO42nd Annual J.P.Morgan Healthcare ConferenceJanuary 9,2024NUPLAZID(pimavanserin)is only approved in the U.S.by the FDA for the treatment of hallucinations and delusions associated with Parkinsons disease psychosis.DAYBUE(trofinetide)is only approved in the U.S.by the FDA for the treat

2、ment of Rett syndrome in adults and pediatric patients two years of age and older.Provided January 9,2024 as part of an oral presentation and is qualified by such;contains forward-looking statements;actual results may vary materially;Acadia disclaims any duty to update.2Forward-Looking StatementsThi

3、s presentation contains forward-looking statements.These statements relate to future events and involve known and unknown risks,uncertainties and other factors which may cause our actual results,performance or achievements to be materially different from any future results,performances or achievemen

4、ts expressed in or implied by such forward-looking statements.Each of these statements is based only on current information,assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties.Forward-looking statements include,but are not limited to,sta

5、tements about(i)plans for,including timing and progress of commercialization or regulatory timelines for,DAYBUE;(ii)benefits to be derived from and efficacy of our product candidates,including the potential advantages of DAYBUE and expansion opportunities for DAYBUE;(iii)estimates regarding the prev

6、alence of Rett syndrome;(iv)potential markets for any of our products,including NUPLAZID and DAYBUE;(v)our estimates regarding our future financial performance,cash position or capital requirements.In some cases,you can identify forward-looking statements by terms such as“may,”“will,”“should,”“could